Harvard Bioscience (NASDAQ:HBIO) Stock Passes Below 200-Day Moving Average of $4.07

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.07 and traded as low as $2.77. Harvard Bioscience shares last traded at $2.79, with a volume of 56,748 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th.

Harvard Bioscience Stock Performance

The stock has a 50-day moving average of $3.21 and a 200 day moving average of $4.06. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 0.94. The stock has a market capitalization of $120.30 million, a price-to-earnings ratio of -13.85 and a beta of 1.31.

Insiders Place Their Bets

In related news, CEO James W. Green bought 10,000 shares of Harvard Bioscience stock in a transaction on Thursday, June 13th. The shares were purchased at an average price of $2.91 per share, for a total transaction of $29,100.00. Following the completion of the acquisition, the chief executive officer now owns 3,111,091 shares in the company, valued at $9,053,274.81. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Harvard Bioscience news, CEO James W. Green acquired 10,000 shares of the business’s stock in a transaction dated Thursday, June 13th. The shares were acquired at an average price of $2.91 per share, for a total transaction of $29,100.00. Following the acquisition, the chief executive officer now directly owns 3,111,091 shares of the company’s stock, valued at approximately $9,053,274.81. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James W. Green acquired 20,000 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were acquired at an average price of $3.07 per share, for a total transaction of $61,400.00. Following the acquisition, the chief executive officer now directly owns 3,101,091 shares in the company, valued at $9,520,349.37. The disclosure for this purchase can be found here. Company insiders own 9.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund boosted its stake in Harvard Bioscience by 3.2% in the 4th quarter. New York State Common Retirement Fund now owns 142,460 shares of the medical instruments supplier’s stock valued at $762,000 after purchasing an additional 4,463 shares during the period. Bailard Inc. bought a new stake in Harvard Bioscience in the 4th quarter valued at $106,000. Acuitas Investments LLC lifted its position in shares of Harvard Bioscience by 35.0% during the 4th quarter. Acuitas Investments LLC now owns 326,516 shares of the medical instruments supplier’s stock valued at $1,747,000 after acquiring an additional 84,735 shares during the period. AMH Equity Ltd lifted its position in shares of Harvard Bioscience by 1.0% during the 4th quarter. AMH Equity Ltd now owns 2,162,893 shares of the medical instruments supplier’s stock valued at $11,571,000 after acquiring an additional 21,540 shares during the period. Finally, Corsair Capital Management L.P. bought a new stake in shares of Harvard Bioscience during the 4th quarter valued at $356,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.